LIVE POLIO IRUS VACCINES

Index 621
Markush, R. E., paper 435-444, 445-456
Martin, R., 532
Martins da Silva, Mauricio, paper 547-560, 561-568;
6-7, 294, 437, 444, 574
Masaya, Nicaragua
epidemic, 1959-60, 547
Mass vaccination, see Field trials, Feeding schedules
Massachusetts
47% of paralytic cases had three Salk injections,
375, 435
Maternal antibodies, see Antibodies, maternal
Mathers, John E., paper 207-227
Mathey, Wayne E., paper 341-354, 357-364
Mauritius
attack rates in Salk and non-Salk vaccinated, 480
field trial, 1959, 475-477
McBride, W. D., 7, 47, 53, 66
McKelvey, John L., paper 207-227
Measles
developmental defects in fetus. 215
infectivity pattern, 410
possibility of severe epidemic, 86
spread compared with polio, 411
tolerance relation, 328
Measles-like virus, see Simian virus
Medellín, Colombia
polio seronegative indices by age, 369
Medical care system
Sottunga, 535
Medicine droppers
vaccine administration, 145, 216, 309
Medium 199
chicken serum, 80
MEF-1, see Vaccine, Attenuated, Type 2, MEF-1
(Lederle-Cox), Poliomyelitis virus, Type 2,
MEF-1
Melnick, Joseph, paper 12-27; 6-7, 28-29, 33-36, 43,
58, 66, 77, 90, 98, 132, 143, 156, 158, 199,
238, 373, 410-411, 431
Melnick, Matilda Benyesh-, see Benyesh-Melnick,
Matilda
Melnick method
determination of extent of lesions in spinal cord,
31, 69
Méndez, Oscar Vargas-, see Vargas-Méndez, Oscar
Menzin, A. W., paper 435-444, 445-456
Mergatherm termal regulators
fluctuations of temperature not exceeding 0.05 ° C,
132
Metabolic inhibition test
antibody determination, 302, 330, 439
Mexican Institute of Social Security, 401
Mexico
field trial, 386-409
isolates of vaccinees, 18, 24, 123
Sabin vaccine, tested, 580
Mexico, Ministry of Health, 386, 401
Mexico City
orphanage study, 1957, 386
rehabilitation treatment, 557
382 cases reported after vaccination, 396
vaccination program, 386, 411
Miami, Florida, field trial, see under Dade County,
Florida
Miami Pediatric Society, 436
Miami University, Bureau of Business and Economic
Research, 438
School of Medicine, 436, 439
Michaels, Richard H., paper 315-321, 377-385; 101
Michigan, University
chimpanzee studies, 157
Microbiological Associates, Bethesda, Maryland
antibody determinations, 439
Middle America Research Unit Laboratory, Panama,
553, 569
Milk,
vehicle, 278, 294
Milk, Human
and active resistance to vaccination, 324-325
Minneapolis
climate and spread study, 163
mass trial, 31,000 participants, 461
Minneapolis Tribune
public opinion poll, 462
Minnesota
epidemiological observations and trial size, 445-446
field trial, 161-173, 341-354, 357-364
two hundred paralytic cases, 1959, 376
Minnesota Department of Health, 345, 348, 462
Minnesota, University
Grove East test, 342
Hospitals, 215
Medical School, 207
Mirkowski, Dr.- (of Lublin, Poland), 527, 530
Mironova, L. L., paper 413-428
Mirski, B., paper 522-531
Miyares, Carlos Hernández, see Hernández Miyares,
Carlos
Moldavian SSR
children immunized to 14-18 years, 486, 488
incidence of paralytic polio, 485, 494
susceptible population computed, 489-490
two programs, 1960, 419, 581-582
Mombassa, Kenya
increase in poliomyelitis cases, 479
Monkeys, see also African green monkey, Cynomolgus,
Grivet, Rhesus, Vervet
experimental infection, 68
foamy agent in 3% from China and Viet Nam, 88
gamma globulin to prevent paralysis, 100
inapparent infections, 202
inoculations and elution marker study, 43
pathogenic qualities related to markers, 21-22, 46
vaccine and virulent polio in, 23
Monkey-kidney tissue cultures, 14, 68, 114, 124, 188-
189, 208, 241, 271, 309, 359, 363, 377
detection of new simian virus, 79-85
in cytopathogenic tests, 229
in elution marker study, 42
in reproductive capacity temperature study, 101
of African green-monkey, technique, 80, 83
single passage may alter T character, 28, 109, 131
test for vacuolating agent in vervet, 87
vaccine test, 505